Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.
BACKGROUND
The effectiveness and safety of pegfilgrastim during bleomycin, etoposide and cisplatin (BEP) chemotherapy have not yet been investigated.


PATIENTS AND METHODS
Patients with germ cell tumors (GCTs) who received pegfilgrastim during BEP at the Kanazawa University Hospital between January 2014 and December 2016 were retrospectively analyzed. The frequency of adverse events and effectiveness in inhibiting neutropenia were compared between cycles using pegfilgrastim and those using filgrastim.


RESULTS
Pegfilgrastim and filgrastim were administered in 13 and 22 cycles, respectively. The absolute neutrophil count at the nadir was significantly lower in patients receiving pegfilgrastim than in those receiving filgrastim (p=0.003). The duration of grade 2-4 neutropenia in cycles using filgrastim was significantly longer than that in those pegfilgrastim (p=0.01). No significant differences in the incidence of febrile neutropenia and serious adverse events were observed.


CONCLUSION
Pegfilgrastim can be safely and effectively administrated during BEP for patients with GCT.
['Iwamoto|Hiroaki|H|', 'Izumi|Kouji|K|', 'Natsagdorj|Ariunbold|A|', 'Makino|Tomoyuki|T|', 'Nohara|Takahiro|T|', 'Shigehara|Kazuyoshi|K|', 'Kadono|Yoshifumi|Y|', 'Mizokami|Atsushi|A|']
D000328:Adult D000971:Antineoplastic Combined Chemotherapy Protocols D001761:Bleomycin D002945:Cisplatin D064420:Drug-Related Side Effects and Adverse Reactions D005047:Etoposide D005260:Female D000069585:Filgrastim D006801:Humans D008297:Male D008875:Middle Aged D009373:Neoplasms, Germ Cell and Embryonal D009503:Neutropenia D011092:Polyethylene Glycols D012189:Retrospective Studies
pegfilgrastim BEP germ cell tumor neutropenia